Multicomponent meningococcal vaccine
A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.
1. A composition comprising:
(i) isolated N. meningitidis outer membrane vesicles;
(ii) at least one isolated N. meningitidis antigenic protein, wherein said at least one isolated N. meningitidis antigenic protein
(a) has been extracted from an outer membrane of an N. meningitidis bacterium; or
(b) is a recombinant N. meningitidis antigenic protein; and
(iii) alum in an amount effective as an adjuvant;
wherein said isolated N. meningitidis outer membrane vesicles are from a first strain of N. meningitidis and said at least one isolated N. meningitidis antigenic protein is from a second strain of N. meningitidis different from the first,
said at least one isolated N. meningitidis antigenic protein is not transferrin binding protein A (TbpA) nor transferrin binding protein B (TbpB), and
the N. meningitidis outer membrane vesicles are isolated by desoxycholate treatment.
2. The composition of claim 1 , wherein said composition comprises a plurality of isolated N. meningitidis antigenic proteins from different strains of N. meningitidis.
3. The composition of claim 1 , wherein said at least one isolated N. meningitidis antigenic protein is an isolated N. meningitidis antigenic proteoglycan.
4. The composition of claim 1 , wherein said at least one isolated N. meningitidis antigenic protein is an isolated N. meningitidis protein selected from the group consisting of a surface antigen, a periplasmic protein, a superoxide dismutase, and a glycoprotein.
5. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
6. The composition of claim 1 , wherein the composition is obtained by a process comprising:
(i) obtaining the isolated N. meningitidis outer membrane vesicles from a first strain of N. meningitidis;
(ii) obtaining the at least one isolated N. meningitidis antigenic protein from a second strain of N. meningitidis different from the first; and
(iii) combining the at least one isolated N. meningitidis antigenic protein with the isolated N. meningitidis outer membrane vesicles.
7. A vaccine composition comprising:
(i) outer membrane vesicles from a first strain of N. meningitidis;
(ii) an isolated antigenic protein from a second strain of N. meningitidis different from the first, wherein said isolated antigenic protein
(a) has been extracted from an outer membrane of an N. meningitidis bacterium; or
(b) is a recombinant N. meningitidis antigenic protein; and
(iii) a pharmaceutically acceptable carrier comprising alum in an amount effective as an adjuvant,
wherein said isolated antigenic protein is not transferrin binding protein A (TbpA) nor transferrin binding protein B (TbpB), and
the N. meningitidis outer membrane vesicles are isolated by desoxycholate treatment.
8. The vaccine composition of claim 7 , wherein said isolated antigenic protein is an N. meningitidis protein selected from the group consisting of a surface antigen, a periplasmic protein, a superoxide dismutase, and a glycoprotein.
9. The composition of claim 1 , wherein said at least one isolated N. meningitidis antigenic protein comprises a surface antigen.
10. The composition of claim 2 , wherein said at least one isolated N. meningitidis antigenic protein comprises a surface antigen.
11. The composition of claim 5 , wherein said at least one isolated N. meningitidis antigenic protein comprises a surface antigen.
12. The composition of claim 6 , wherein said at least one isolated N. meningitidis antigenic protein comprises a surface antigen.
13. The composition of claim 7 , wherein said isolated N. meningitidis antigenic protein comprises a surface antigen.
14. The vaccine composition of claim 7 , wherein said vaccine composition comprises a plurality of isolated N. meningitidis antigenic proteins from different strains of N. meningitidis.
15. A vaccine composition comprising:
(i) outer membrane vesicles from a first strain of N. meningitidis;
(ii) an isolated antigenic protein from a second strain of N. meningitidis different from the first, wherein said isolated antigenic protein
(a) has been extracted from an outer membrane of an N. meningitidis bacterium; or
(b) is a recombinant N. meningitidis antigenic protein; and
(iii) a pharmaceutically acceptable carrier comprising an adjuvant,
wherein the adjuvant is alum adjuvant,
wherein said isolated antigenic protein is not transferrin binding protein A (TbpA) nor transferrin binding protein B (TbpB), and
the N. meningitidis outer membrane vesicles are isolated by desoxycholate treatment.
16. The vaccine composition of claim 15 , wherein said isolated antigenic protein is an N. meningitidis protein selected from the group consisting of a surface antigen, a periplasmic protein, a superoxide dismutase, and a glycoprotein.
17. The composition of claim 15 , wherein said isolated N. meningitidis antigenic protein comprises a surface antigen.
18. The vaccine composition of claim 15 , wherein said vaccine composition comprises a plurality of isolated N. meningitidis antigenic proteins from different strains of N. meningitidis.